Procter & Gamble Health Q2 FY24: Revenue ₹1230 Cr, PAT ₹229 Cr
Q2 FY24 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹305Cr
- Net profit
- ₹66Cr
- Margin
- 29%
Guidance rank: #75 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Procter & Gamble Health Ltd Q2 FY24 key numbers
- Revenue
- Reported Profit After Tax (PAT): ₹229 crore.
As stated in Procter & Gamble Health Ltd's Q2 FY24 investor presentation · published 25 Sept 2026. Reported figures, not investment advice.
Based on Procter & Gamble Health Ltd's Q2 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Reported revenue: ₹1230 crore (page 17) - Reported Profit After Tax (PAT): ₹229 crore (page 17) - Volume figure: 1.6 lakh units deployed across India (page 13)
From Procter & Gamble Health Ltd's Q2 FY24 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Reported revenue: ₹1230 crore (page 17)
- Reported Profit After Tax (PAT): ₹229 crore (page 17)
- Volume figure: 1.6 lakh units deployed across India (page 13)
Profitability & Margins
See what Procter & Gamble Health Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Procter & Gamble Health Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Procter & Gamble Health Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Procter & Gamble Health Ltd said on order book & pipeline — free account, 30 seconds.
Procter & Gamble Health Ltd — Quarterly revenue & net profit
Procter & Gamble Health Ltd Q2 FY24 results — key figures
| ₹ Cr | Q2 FY24 |
|---|---|
| Revenue | 305 |
| Operating profit (EBITDA) | 89 |
| Operating margin | 29% |
| Profit before tax | 88 |
| Net profit (PAT) | 66 |
| EPS (₹) | 39.50 |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹382 Cr, net profit ₹112 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What P & G Health Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals (Q2 FY24)
Revenue**: ₹6,435 crore, up 19% year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY24 earnings call — and how it ranks against sector…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Procter & Gamble Health Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Procter & Gamble Health Ltd Q2 FY24 results?
Reported revenue: ₹1230 crore (page 17) - Reported Profit After Tax (PAT): ₹229 crore (page 17) - Volume figure: 1.6 lakh units deployed across India (page 13)
What is Procter & Gamble Health Ltd share price analysis?
Procter & Gamble Health Ltd currently shows a neutral. The stock trades at a P/E of 27.4 with a market cap of ₹9,135 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Procter & Gamble Health Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
